GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1167 participants.

Also called NCT04796428

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,167 participants (planned count) (from the registry)
Sponsor
Center for Outcomes Research and Clinical Epidemiology, Italy (from the registry)
Registry
  • NCT NCT04796428
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04796428. Randomized; single masking; primary purpose treatment. Start 2021-06-30 (anticipated); primary completion 2023-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial
Acronym
GOLDEN-AGE
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Canagliflozin
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Empagliflozin
Lead sponsor
Center for Outcomes Research and Clinical Epidemiology, Italy (class: other)
Collaborator
Italian Society of Diabetology (class: other)

Record details

Record id
cardio:ct-nct04796428
Content hash
fcb794a5474d3b63e47f64f1a0236a0c8d18a530ea53a1330b2b6b0a81f7bbc2